Literature DB >> 15855548

High levels of antimicrobial coresistance among extended-spectrum-beta-lactamase-producing Enterobacteriaceae.

Mitchell J Schwaber1, Shiri Navon-Venezia, David Schwartz, Yehuda Carmeli.   

Abstract

We compared the susceptibility of 312 extended-spectrum beta-lactamase (ESBL)-producing Enterobacteriaceae isolates with that of 1,216 ESBL nonproducers. Of ESBL producers, 25% were susceptible to gentamicin, 30% to trimethoprim-sulfamethoxazole, 41% to ciprofloxacin, and 60% to piperacillin-tazobactam. ESBL nonproducers were more often susceptible to these agents. ESBL-producing Enterobacteriaceae represent a major source of resistance to various antibiotics.

Entities:  

Mesh：

Substances：

Year:  2005        PMID： 15855548      PMCID： PMC1087677          DOI： 10.1128/AAC.49.5.2137-2139.2005

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  15 in total

1.  Antibiotic resistance in 1962 invasive isolates of Escherichia coli in 27 Spanish hospitals participating in the European Antimicrobial Resistance Surveillance System (2001).

Authors:  J Oteo; J Campos; F Baquero
Journal:  J Antimicrob Chemother       Date:  2002-12       Impact factor: 5.790

Review 2.  The role of mutators in the emergence of antibiotic-resistant bacteria.

Authors:  Ian Chopra; Alexander J O'Neill; Keith Miller
Journal:  Drug Resist Updat       Date:  2003-06       Impact factor: 18.500

3.  Extended-spectrum beta-lactamases among Enterobacter isolates obtained in Tel Aviv, Israel.

Authors:  Jacob Schlesinger; Shiri Navon-Venezia; Inna Chmelnitsky; Orly Hammer-Münz; Azita Leavitt; Howard S Gold; Mitchell J Schwaber; Yehuda Carmeli
Journal:  Antimicrob Agents Chemother       Date:  2005-03       Impact factor: 5.191

4.  Patterns of resistance associated with integrons, the extended-spectrum beta-lactamase SHV-5 gene, and a multidrug efflux pump of Klebsiella pneumoniae causing a nosocomial outbreak.

Authors:  Paul Gruteke; Wil Goessens; Jan Van Gils; Paul Peerbooms; Nicole Lemmens-Den Toom; Marga Van Santen-Verheuvel; Alex Van Belkum; Henri Verbrugh
Journal:  J Clin Microbiol       Date:  2003-03       Impact factor: 5.948

5.  Extended-spectrum beta-lactamases: frequency, risk factors, and outcomes.

Authors:  Allison E Einhorn; Melinda M Neuhauser; David T Bearden; John P Quinn; Susan L Pendland
Journal:  Pharmacotherapy       Date:  2002-01       Impact factor: 4.705

6.  Epidemiology of ciprofloxacin resistance and its relationship to extended-spectrum beta-lactamase production in Klebsiella pneumoniae isolates causing bacteremia.

Authors:  D L Paterson; L Mulazimoglu; J M Casellas; W C Ko; H Goossens; A Von Gottberg; S Mohapatra; G M Trenholme; K P Klugman; J G McCormack; V L Yu
Journal:  Clin Infect Dis       Date:  2000-03       Impact factor: 9.079

7.  Prevalence of extended spectrum beta-lactamase (ESBL)-producing clinical isolates in the Asia-Pacific region and South Africa: regional results from SENTRY Antimicrobial Surveillance Program (1998-99).

Authors:  Jan M Bell; John D Turnidge; Ana C Gales; Michael A Pfaller; Ronald N Jones
Journal:  Diagn Microbiol Infect Dis       Date:  2002-03       Impact factor: 2.803

8.  Prevalence of plasmid-mediated quinolone resistance.

Authors:  George A Jacoby; Nancy Chow; Ken B Waites
Journal:  Antimicrob Agents Chemother       Date:  2003-02       Impact factor: 5.191

9.  Occurrence and phenotypic characteristics of extended-spectrum beta-lactamases among members of the family Enterobacteriaceae at the Tel-Aviv Medical Center (Israel) and evaluation of diagnostic tests.

Authors:  Shiri Navon-Venezia; Orly Hammer-Munz; David Schwartz; Dan Turner; Boris Kuzmenko; Yehuda Carmeli
Journal:  J Clin Microbiol       Date:  2003-01       Impact factor: 5.948

10.  Utility of NCCLS guidelines for identifying extended-spectrum beta-lactamases in non-Escherichia coli and Non-Klebsiella spp. of Enterobacteriaceae.

Authors:  Mitchell J Schwaber; Patti M Raney; J Kamile Rasheed; James W Biddle; Portia Williams; John E McGowan; Fred C Tenover
Journal:  J Clin Microbiol       Date:  2004-01       Impact factor: 5.948
View more
  46 in total

1.  The association between antibiotic use and resistance: the role of secondary antibiotics.

Authors:  J A Bosso; P D Mauldin; C D Salgado
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2010-06-10       Impact factor: 3.267

2.  Endocarditis caused by extended-spectrum-beta-lactamase-producing Klebsiella pneumoniae: emergence of resistance to ciprofloxacin and piperacillin-tazobactam during treatment despite initial susceptibility.

Authors:  Oren Zimhony; Inna Chmelnitsky; Rita Bardenstein; Sorel Goland; Orly Hammer Muntz; Shiri Navon Venezia; Yehuda Carmeli
Journal:  Antimicrob Agents Chemother       Date:  2006-09       Impact factor: 5.191

3.  Clinical and economic impact of bacteremia with extended- spectrum-beta-lactamase-producing Enterobacteriaceae.

Authors:  Mitchell J Schwaber; Shiri Navon-Venezia; Keith S Kaye; Ronen Ben-Ami; David Schwartz; Yehuda Carmeli
Journal:  Antimicrob Agents Chemother       Date:  2006-04       Impact factor: 5.191

4.  Predictors of mortality in patients with bloodstream infections caused by extended-spectrum-beta-lactamase-producing Enterobacteriaceae: importance of inadequate initial antimicrobial treatment.

Authors:  Mario Tumbarello; Maurizio Sanguinetti; Eva Montuori; Enrico M Trecarichi; Brunella Posteraro; Barbara Fiori; Rita Citton; Tiziana D'Inzeo; Giovanni Fadda; Roberto Cauda; Teresa Spanu
Journal:  Antimicrob Agents Chemother       Date:  2007-03-26       Impact factor: 5.191

5.  In vitro activity of fosfomycin against extended-spectrum-beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae: comparison of susceptibility testing procedures.

Authors:  M de Cueto; L López; J R Hernández; C Morillo; A Pascual
Journal:  Antimicrob Agents Chemother       Date:  2006-01       Impact factor: 5.191

6.  Changes in qnr prevalence and fluoroquinolone resistance in clinical isolates of Klebsiella pneumoniae and Enterobacter spp. collected from 1990 to 2005.

Authors:  Jacob Strahilevitz; Dalia Engelstein; Amos Adler; Violeta Temper; Allon E Moses; Colin Block; Ari Robicsek
Journal:  Antimicrob Agents Chemother       Date:  2007-05-25       Impact factor: 5.191

Review 7.  Clinical and economic impact of common multidrug-resistant gram-negative bacilli.

Authors:  Christian G Giske; Dominique L Monnet; Otto Cars; Yehuda Carmeli
Journal:  Antimicrob Agents Chemother       Date:  2007-12-10       Impact factor: 5.191

8.  Antibiotic coresistance in extended-spectrum-beta-lactamase-producing Enterobacteriaceae and in vitro activity of tigecycline.

Authors:  María-Isabel Morosini; María García-Castillo; Teresa M Coque; Aránzazu Valverde; Angela Novais; Elena Loza; Fernando Baquero; Rafael Cantón
Journal:  Antimicrob Agents Chemother       Date:  2006-08       Impact factor: 5.191

9.  Prevalence of Aminoglycoside-Modifying Enzymes in Escherichia coli and Klebsiella pneumoniae Producing Extended Spectrum β-Lactamases Collected in Two Multicenter Studies in Spain.

Authors:  Marta Fernández-Martínez; Belén Ruiz Del Castillo; Maria Jesús Lecea-Cuello; Jesús Rodríguez-Baño; Álvaro Pascual; Luis Martínez-Martínez
Journal:  Microb Drug Resist       Date:  2017-10-03       Impact factor: 3.431

10.  Ertapenem resistance among extended-spectrum-beta-lactamase-producing Klebsiella pneumoniae isolates.

Authors:  Azita Leavitt; Inna Chmelnitsky; Raul Colodner; Itzhak Ofek; Yehuda Carmeli; Shiri Navon-Venezia
Journal:  J Clin Microbiol       Date:  2009-02-11       Impact factor: 5.948
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.